Drugs / NIB101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05192174 | Jan 2022 → May 2025 | cancer | Noile-Immune Biotech, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIB101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05192174 ↗ |
| Route | Intravenous | “will be administered intravenously on Day 0” NCT05192174 ↗ |